Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 2945 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Umotif–SEVERAL: investment, 202009 financing round Series A £5m led by existing investor AlbionVC 2020-09-03
Evotec–Univ Oxford: biobanking, 202009– collab €na granting Evotec access to QUOD biobank for multi-omics analyses for drug discovery 2020-09-02
AstraZeneca–Oxford BioMedica: contract manufacturing, 202009– supply production capacity for adenoviral vector-based Covid-19 vaccine AZD1222 2020-09-01
Biocartis–LifeArc: molecular diagnostics, 202009– collab expansion €na developm of MDx tests for infectious + immune diseases for Idylla platform 2020-09-01
Axol Bioscience–Zyme Communications: public relations, 202008 service existent by Zyme 2020-08-27
Takeda–Engitix: antifibrotics, 202008– collab + license agreem up to $500m+ developm for advanced liver diseases incl NASH 2020-08-25
F2G Ltd–Advent Venture Partners: investment, 202008 financing round totalling $60.8m incl exisiting investor Advent Life Sciences 2020-08-12
F2G Ltd–Cowen: investment, 202008 financing round totalling $60.8m incl new investor Cowen Healthcare Investments 2020-08-12
F2G Ltd–EMS (BR): investment, 202008 financing round totalling $60.8m incl exisiting investor Brace Pharma Capital 2020-08-12
F2G Ltd–Morningside: investment, 202008 financing round totalling $60.8m incl exisiting investor Morningside Ventures 2020-08-12
F2G Ltd–Novo Group: investment, 202008 financing round totalling $60.8m incl exisiting investor Novo Ventures 2020-08-12
F2G Ltd–SEVERAL: investment, 202008 financing round $60.8m from new investor Cowen Healthcare Investments + existing investors 2020-08-12
Bayer–Linklaters: legal services, 202008 supply service legal counsel with regard to acquisition of Kandy Therapeutics by Bayer 2020-08-11
Bayer–Morgan Stanley: financial services, 202008 supply service financial advisor with regard to acquisition of Kandy Therapeutics by Bayer 2020-08-11
Kandy Therapeutics–Bayer: investment, 202008– acquisition $425m upfront + $450m developm milestones + triple digit $m sales milestones 2020-08-11
Kandy Therapeutics–Goldman Sachs: financial services, 202008 supply service financial advisor with regard to acquisition of Kandy Tx by Bayer 2020-08-11
Kandy Therapeutics–Goodwin Procter: legal services, 202008 supply service legal counsel with regard to acquisition of Kandy Therapeutics by Bayer 2020-08-11
Oasmia–Consilium: public relations, 202008 service existent by CSC 2020-08-10
NBE Therapeutics–Optimum Strategic Communications: public relations, 202008 service existent by Optimum 2020-08-03
Genespire–Consilium: public relations, 202007 service existent by CSC 2020-07-30
Abzena–Biospring Partners: investment, 202007 investment $10m by Lifespring Partners 2020-07-28
Enthera–Instinctif Partners: public relations, 202007 service existent by Instinctif 2020-07-28
Optimapharm–Coulter Partners: recruitment services, 202007 supply service placement of Andrew Copestake as CEO at Optimapharm 2020-07-28
Macomics–Epidarex Capital: investment, 202007 seed financing round totalling £3.2m incl lead investor Epidarex Capital 2020-07-14
Macomics–Scotland (govt): investment, 202007 seed financing round totalling £3.2m incl co-investor SIB 2020-07-14
Macomics–SEVERAL: investment, 202007 seed financing round £3.2m led by Epidarex Capital + incl SIB 2020-07-14
Eir Ventures–Optimum Strategic Communications: public relations, 202007 service existent by Optimum 2020-07-10
VarmX–Instinctif Partners: public relations, 202007 service existent by Instinctif 2020-07-08
Mission Therapeutics–Instinctif Partners: public relations, 202007 service existent by Instinctif 2020-07-06
Mission Therapeutics–Pfizer: investment, 202007 financing round totalling £12m ($15m) incl existing + lead investor Pfizer Ventures 2020-07-06
Mission Therapeutics–SEVERAL: investment, 202007 financing round £12m ($15m) led by existing investor Pfizer Ventures 2020-07-06
Scenic Biotech–Netherlands (govt): credit, 202006– Innovation Credit €3.1m from RVO to advance QPCTL inhibitors 2020-06-23
Epidarex Capital–Huntsworth: public relations, 202006 service existent by Citigate Dewe Rogerson 2020-06-22
Epidarex Capital–SEVERAL: investment, 202006 closing £102.1m of Epidarex Capital III UK LP with £50m from lead investor British Business Bank 2020-06-22
Epidarex Capital–Strathclyde Pension Fund: investment, 202006 closing totalling £102.1m of Epidarex Capital III UK LP incl co-investor SPF 2020-06-22
Epidarex Capital–United Kingdom (govt): investment, 202006 closing totalling £102.1m of Epidarex Capital III UK LP incl £50m from lead investor BBB 2020-06-22
Epidarex Capital–Univ Aberdeen: investment, 202006 closing totalling £102.1m of Epidarex Capital III UK LP incl co-investor Univ Aberdeen 2020-06-22
Epidarex Capital–Univ Edinburgh: investment, 202006 closing totalling £102.1m of Epidarex Capital III UK LP incl co-investor Univ Edinburgh 2020-06-22
Epidarex Capital–Univ Glasgow: investment, 202006 closing totalling £102.1m of Epidarex Capital III UK LP incl co-investor Univ Glasgow 2020-06-22
Epidarex Capital–Univ Manchester: investment, 202006 closing totalling £102.1m of Epidarex Capital III UK LP incl co-investor Univ Manchester 2020-06-22
GSK–Ideaya Biosciences: synthetic lethality, 202006– collab strategic partnership ww $100m upfront + milestones + royalties 2020-06-16
Ideaya Biosciences–GSK: investment, 202006 direct private placement $20m common stock purchase by GSK 2020-06-16
Ona Therapeutics–Optimum Strategic Communications: public relations, 202006 service existent by Optimum 2020-06-16
Ikarovec–United Kingdom (govt): grant, 202006 Innovate UK grant £460k for developm of gene therapy for wet AMD 2020-06-15
Bit Bio–ARCH Venture: investment, 202006 financing round Series A totalling $41.5m incl co-investor Arch Venture Partners 2020-06-13
Bit Bio–BY Capital: investment, 202006 financing round Series A totalling $41.5m incl co-investor BlueYard Capital 2020-06-13
Bit Bio–Foresite Capital: investment, 202006 financing round Series A totalling $41.5m incl co-investor Foresite Capital 2020-06-13
Bit Bio–Mission Group: public relations, 202006 service existent by April Six 2020-06-13
Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Bob Nelsen 2020-06-13
Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Jim Tananbaum 2020-06-13
Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Rick Klaunser 2020-06-13
Bit Bio–SEVERAL: investment, 202006 financing round Series A $41.5m led by Rick Klaunser + Bob Nelsen + Jim Tananbaum 2020-06-13
Valo Therapeutics–Scius Communications: public relations, 202006 supply service existent by Scius Communications 2020-06-08
Tropic Biosciences–SEVERAL: investment, 202006 financing round Series B $28.5m led by Temasek 2020-06-04
Tropic Biosciences–Temasek: investment, 202006 financing round Series B totalling $28.5m incl new + lead investor Temasek 2020-06-04
Base Genomics–SEVERAL: investment, 202006 seed financing round £9m ($11m) led by Oxford Sciences Innovation 2020-06-03
Base Genomics–Univ Oxford: investment, 202006 seed financing round totalling £9m incl lead investor Oxford Sciences Innovation 2020-06-03
Base Genomics–Zyme Communications: public relations, 202006 service existent by Zyme 2020-06-03
NodThera–SEVERAL: investment, 202006 financing round Series B £44m ($55m) led by Novo Ventures 2020-06-03
Prilenia–Instinctif Partners: public relations, 202006 service existent by Instinctif 2020-06-03
Rigenerand–Image Box: public relations, 202005– supply service by Image Box PR 2020-05-29
Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital 2020-05-26
GSK–Samsung: biologicals contract manufacturing, 202005–2028 supply up to $231m of Benlysta + other biologics by Samsung Biologics 2020-05-21
HotSpot Therapeutics–GSK: investment, 202005 financing round Series B totalling $65m incl lead investor SR One 2020-05-21
HotSpot Therapeutics–SEVERAL: investment, 202005 financing round Series B $65m led by SR One 2020-05-21
Rentschler–Horizon Discovery: cell line development, 202005– license to CHOSource platform for cell line developm for difficult-to-express proteins 2020-05-19
Holmusk–SEVERAL: investment, 202005 financing round Series A $21.5m co-led by Optum Ventures + Health Catalayst Capital 2020-05-18
Oribiotech–CellGenix: reagents, 202005– collab supply of GMP raw materials for closed-system CGT manufacturing system of Ori 2020-05-13
Polyganics–Instinctif Partners: public relations, 202005 service existent by Instinctif 2020-05-13
Optibrium–OpenEye Scientific: cheminformatics, 202005– collab product integration OE libraries + toolkits with StarDrop software 2020-05-12
Optimapharm–TRG Management: investment, 202005 investment by The Rohatyn Group to grow organically + via acquisitions 2020-05-12
Compass Pathways–Able Partners: investment, 202004 financing round Series B totalling $80m incl new investor Able Partners 2020-04-27
Compass Pathways–ATAI Life Sciences: investment, 202004 financing round Series B totalling $80m incl existing investor ATAI Life Sciences 2020-04-27
Compass Pathways–Camden Partners: investment, 202004 financing round Series B totalling $80m incl new investor Camden Partners Nexus 2020-04-27
Compass Pathways–Founders Fund: investment, 202004 financing round Series B totalling $80m incl new investor Founders Fund 2020-04-27
Compass Pathways–Otsuka: investment, 202004 financing round Series B totalling $80m incl new investor MSRD 2020-04-27
Compass Pathways–Perceptive Advisors: investment, 202004 financing round Series B totalling $80m incl new investor Perceptive Advisors 2020-04-27
Compass Pathways–SEVERAL: investment, 202004 financing round Series B $80m from existing + new investors 2020-04-27
Compass Pathways–Skyviews Life Science: investment, 202004 financing round Series B totalling $80m incl new investor Skyviews Life Science 2020-04-27
Compass Pathways–Soleus Capital: investment, 202004 financing round Series B totalling $80m incl new investor Soleus Capital 2020-04-27
FoRx Therapeutics–Optimum Strategic Communications: public relations, 202004 service existent by Optimum 2020-04-22
Nanna Therapeutics–Astellas: investment, 202004 acquisition 100% for £12m upfront + £57.5m milestones by Astellas Pharma Europe Ltd 2020-04-21
MicrofluidX–88 Capital: investment, 202004 seed financing round totalling £1.4m incl angel contributions from 88 Capital 2020-04-20
MicrofluidX–Cambridge Angels: investment, 202004 seed financing round totalling £1.4m incl angel contributions from Cambridge Angels 2020-04-20
MicrofluidX–Longwall Ventures: investment, 202004 seed financing round totalling £1.4m incl investor Longwall Ventures 2020-04-20
MicrofluidX–Midven: investment, 202004 seed financing round totalling £1.4m incl investor UKI2S 2020-04-20
MicrofluidX–Moulton Goodies: investment, 202004 seed financing round totalling £1.4m incl investor Moulton Goodies Ltd 2020-04-20
MicrofluidX–SEVERAL: investment, 202004 seed financing round £1.4m from UKI2S + Longwall Ventures + Moulton Goodies + angel investors 2020-04-20
Avectas–PERSON: investment, 202004 financing round Series C totalling $20m incl existing + co-lead investor Seamus Mulligan 2020-04-16
Avectas–SEVERAL: investment, 202004 financing round Series C $20m led by exisiting shareholders incl Seamus Mulligan 2020-04-16
Evox Therapeutics–Cevec: cell line technology, 202004– license €na for use of CAP technology to produce exosome therapeutics as part of ongoing collab 2020-04-16
Cerevance–Lightstone Ventures: investment, 202004 financing round Series B totalling $45m incl existing investor Lightstone Ventures 2020-04-14
Cerevance–SEVERAL: investment, 202004 financing round Series B $45m with new investors GV + Bill Gates + Foresite Capital plus existing investors 2020-04-14
Cerevance–United Kingdom (govt): investment, 202004 financing round Series B totalling $45m incl existing investor Dementia Discovery Fund 2020-04-14
Amphista Therapeutics–Advent Venture Partners: investment, 202004 financing round Series A totalling $7.5m incl lead investor Advent Life Sciences 2020-04-07
Amphista Therapeutics–BioMotiv: investment, 202004 financing round Series A totalling $7.5m incl new + co-investor BioMotiv 2020-04-07
Amphista Therapeutics–EU (govt): investment, 202004 financing round Series A totalling $7.5m incl existing seed + co-investor European Investment Fund 2020-04-07
Amphista Therapeutics–Scius Communications: public relations, 202004 supply service existent by Scius Communications 2020-04-07
Amphista Therapeutics–Scotland (govt): investment, 202004 financing round Series A totalling $7.5m incl existing seed + co-investor SIB 2020-04-07
Amphista Therapeutics–SEVERAL: investment, 202004 financing round Series A $7.5m led by Advent Life Sciences + incl SIB + EIF + BioMotiv 2020-04-07
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30  next pagenext page



Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top